Fig. 6: A lower BCL-XL can enhance androgen’s suppression of tumor growth in vivo. | Cell Death & Disease

Fig. 6: A lower BCL-XL can enhance androgen’s suppression of tumor growth in vivo.

From: Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death

Fig. 6

A Nude mouse groups were injected with EnzR-LNCAP cell suspensions (~5 × 106 cells). Mice were injected with enzalutamide (10 mg/kg/week, twice weekly). Bipolar androgen therapy treatment was conducted by injection of Testosterone (200 μg/kg/week, twice weekly) or EtOH at 3th/5th/7th week. Mice were sacrificed after 8 weeks, tumors were removed and measured for studies. B Tumor weights were shown and represented with mean ± SD. C Representative IHC image of BCL-XL expression in tumor tissue samples. *p < 0.05 was considered statistically significant by students’ t-test compare with pLKO+EtOH groups.

Back to article page